Telehealth Pharmacy Transparency
What pharmacy transparency means in telehealth, how 503A and 503B fulfillment differ, and how to verify the pharmacy behind your prescription.
Why does telehealth pharmacy transparency matter?
Pharmacy transparency matters because the pharmacy that compounds and dispenses your medication determines the oversight and quality standards behind it. A transparent provider names its pharmacy and its category — 503A (patient-specific compounding) or 503B (an FDA-registered outsourcing facility under cGMP) — so you can verify the license. Providers that never name a pharmacy make verification impossible.
Disclaimer: American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider. Brand-name medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved under their own applications. Compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products.
503A vs 503B in plain terms
503A pharmacies compound patient-specific prescriptions under state board oversight. 503B outsourcing facilities are FDA-registered and compound larger batches under current good manufacturing practice (cGMP) and FDA inspection. See our detailed 503A vs 503B explainer.
How to verify the pharmacy
- Find the pharmacy named on the provider's site or in your paperwork
- Check the state board of pharmacy license for 503A pharmacies
- Check the FDA registered-outsourcing-facility list for 503B facilities
- Confirm sterile-compounding standards (USP <797>) are referenced
How this connects to pricing
Disclosed sourcing and disclosed pricing tend to travel together. For an independent month-to-month pricing reference and pricing-history archive, the compounded GLP-1 price comparison is a useful cross-check.
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | Patient-specific compounding | FDA-registered facility, larger batches |
| Primary oversight | State board of pharmacy | FDA, under cGMP, subject to inspection |
| How to verify | State board license lookup | FDA registered-outsourcing-facility list |
| Sterile standard | USP <797> | cGMP + USP <797> |
Both operate under oversight; what matters most is that the pharmacy is named, licensed, and verifiable.
Frequently asked questions
What is the difference between 503A and 503B?
503A compounds patient-specific prescriptions under state oversight; 503B is an FDA-registered outsourcing facility compounding under cGMP.
How do I verify my telehealth pharmacy?
Confirm the pharmacy is named, then check the state board license (503A) or the FDA outsourcing-facility list (503B).
Is compounded medication FDA-approved?
No. American Telehealth Review is an editorial resource and does not provide medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved finished drug products and should only be prescribed when clinically appropriate by a licensed healthcare provider.
Sources
- FDA — Compounding: 503A pharmacies and 503B outsourcing facilities.
- U.S. Pharmacopeia — General Chapter <797> Pharmaceutical Compounding, Sterile Preparations.
- U.S. Food & Drug Administration — Compounding and the FDA (fda.gov).